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Abstract 
The aim of this work was to clarify the dynamics behind the influence of ionic strength 
on the changes in drug release from large unilamellar vesicles (LUVs). For this 
purpose, we have investigated the transport of two different model drugs (caffeine 
and hydrocortisone) formulated into liposomes through different types of barriers with 
different retention properties (regenerated cellulose and the newly introduced 
biomimetic barrier, Permeapad®). Drug release from liposomes was studied utilizing 
the standard Franz diffusion cells. LUV dispersions were exposed to the isotonic, 
hypotonic and hypertonic environment (difference of 300 mOsm/kg between the initial 
LUVs and the environment) and experimental data treated with both linear and non-
linear (Korsmeyer-Peppas) regression models. To alter the rigidity of the liposomal 
membranes, cholesterol was introduced in the liposomal barriers (up to 25% w/w). 
Korsmeyer-Peppas model was proven to be suited to analyse experimental data 
throughout the experimental time frame, providing important additive information in 
comparison to standard linear approximation. The obtained results are highly relevant 
as they improve the interpretation of drug release kinetics from LUVs under osmotic 
stress. Moreover, the findings can be utilized in the development of liposomal 
formulations intended for nose-to-brain targeted drug delivery. 
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Abbreviations: EE, entrapment efficiency; hypo, hypotonic environment; hyper, 
hypertonic environment; iso, isotonic environment; K, transport constant; LUVs, large 
unilamellar vesicles; Mt/M∞, fractional permeated drug; n, transport exponent; PBS, 
phosphate buffered saline; PI, polydispersity index; PL, permeability through the 
liposomal bilayer; R2adj, adjusted correlation coefficient; RB, resistance to drug 
transport through the barrier; RL, resistance to drug transport through liposomal 
bilayer; RT, total resistance to drug transport; SD, standard deviation; SPC, soy-






Liposomes are lipid-based vesicles with a nanometric size range (Bangham and 
Horne, 1964, New, 1990). Since liposomes were first described in the 1960s 
(Bangham and Horne, 1964), they have been extensively studied as drug delivery 
systems for both hydrophilic and lipophilic drugs (Allen and Cullis, 2013, Li et al., 
2019). Nasally administered liposomal drug formulations have shown promising 
potentials for the treatment of some brain diseases such as Alzheimer’s and 
Parkinson’s disease (Lai et al., 2013, Vieira and Gamarra, 2016). However, to 
achieve maximal therapeutic benefits, controlled release from the liposomes in the 
nasal cavity is required to obtain optimal available dose at the target site in vivo 
(Bourganis et al., 2018, Lai et al., 2013). 
 
One important parameter that is often underestimated in the development of 
formulations for nasal drug delivery is the variability of physiological conditions at the 
administration site. For example, under normal physiological conditions, the nasal 
mucus tonicity is approximately 300 mOsm/kg (Pedersen et al., 2007). However, this 
value can change considerably as the nasal mucosa is rather sensitive to the 
external environment such as air humidity and temperature (Quraishi et al., 1998). 
For instance, hyperventilation in dry air can increase the human nasal tonicity up to 
450 mOsm/kg (Pedersen et al., 2007). Variation in the ionic strength at the 
administration site is highly relevant for liposomes since they consist of semi-
permeable membrane, and are therefore, highly sensitive to osmosis (Bangham et 
al., 1967, Paula et al., 1996, Pencer et al., 2001). To predict performance of 
liposomes in vivo, good in vitro models that can determine the release kinetics from 
liposomes at the early stage of the liposomal drug development process are 
necessary (Solomon et al., 2017, Wacker, 2017). 
 
Currently, there are no standard methods for studying drug release from liposomes in 
vitro (Nothnagel and Wacker, 2018, Solomon et al., 2017, Wacker, 2017). The 
proposed methods are based on separating the dissolved fraction (released drug) 
from the undissolved fraction (liposomal drug) (Nothnagel and Wacker, 2018). Some 
of the most common methods applied to liposomes are filtration, ultracentrifugation, 
solid phase extraction, and dialysis-based methods (Nothnagel and Wacker, 2018). 




liposomal drug from released drug (Solomon et al., 2017). The liposomal formulation 
is placed in the donor compartment which is separated from the acceptor 
compartment by a barrier that can exhibit low retention (e.g. dialysis barrier) or high 
retention (e.g. biomimetic, biologic barrier) to drug permeation (Nothnagel and 
Wacker, 2018). Disadvantages regarding the dialysis-based methods are related to 
violation of sink condition (Solomon et al., 2017), and the fact that drug released from 
liposomes needs to cross an additional barrier before being quantified (Fig. 1) 
(Nothnagel and Wacker, 2018, Wacker, 2017). On the other hand, dialysis-based 
methods are convenient, cost-effective and simple. Consequently, the dialysis-based 
devices have been implemented into USP dissolution apparatuses (e.g. glass basket, 
dispersion releaser, flow-through), and used in the development of in situ methods 
(Nothnagel and Wacker, 2018, Solomon et al., 2017, Tang et al., 2019, Yuan et al., 
2017). It has to be mentioned that the improved dialysis-based methods are still 
limited by the barrier properties that separates the liposomal drug from released drug. 
Therefore, more processing of the diffusion data is still required for correct 
interpretation of the release mechanism from liposomes (Jain and Jain, 2016, 
Wacker, 2017). 
 
The most common way to treat diffusion data is by simple zero order mass transport 
kinetic (Brandl et al., 2007, Brodin et al., 2010, Nothnagel and Wacker, 2018). In both 
previous studies (Wu et al., 2017, Wu et al., 2019), we applied a zero order model to 
interpret the mass transport data. The release from liposomes was calculated by 
using a reference experiment of free drug solution (Wu et al., 2019). We observed 
that the release kinetics from liposomes were altered due to tonicity perturbations in 
the external environments (i.e. uneven ionic strength within inner core and external 
environment of liposomes). Moreover, we noticed that when the osmotic stress was 
applied, the drug transport profiles through regenerated cellulose barrier showed 
deviations from linearity, indicating possible modifications of the drug release kinetics 
from the liposomes over time. In such situations, the non-linear regression models for 
data fitting could have been applied to analyse the diffusion data (Jain and Jain, 
2016). 
 
The non-linear regression models such as Higuchi and Korsmeyer-Peppas are the 




and Sousa Lobo, 2001, Jain and Jain, 2016). The Korsmeyer-Peppas model has 
previously been successfully used to describe the drug release kinetics from 
liposomes (Haghiralsadat et al., 2018, Jain and Jain, 2016). In this study, 




= 𝐾 ∙ 𝑡  
(1) 
In this equation, Mt/M∞ represents the fractional permeated drug, t is the time, K is 
the transport constant (dimension of time-1), and n is the transport exponent 
(dimensionless). The release constant K provides mostly information on the drug 
formulation such as structural characteristics of the nanocarriers, whereas n is 
important since it is related to the drug release mechanism (i.e. Fickian diffusion or 
non-Fickian diffusion). In the case of liposomes and assuming sink conditions, the 
flux of the drug (j) through a low retention barrier (e.g. regenerated cellulose) of 
constant thickness (x) can be described by Eq.(2) (simplified Fick’s first law); 
𝑗 = 𝐷




In this equation, c0d is the freely dissolved unentrapped drug concentration outside 
liposomes in the donor compartment, ca the acceptor drug concentration and D is the 
diffusion coefficient. According to this model, the net flux of drug through the barrier is 
the result of two diffusion mechanisms (Fig. 1). One is the diffusion of drug molecules 
from the donor compartment to the acceptor compartment (experimentally measured 
K, Fig. 1). The second is the diffusion through the phospholipid bilayer of liposomes 
that is dependent on the liposomal release rate (KI, Fig. 1). In the case where K≈KI , 
the gradient of concentration (driving force of the diffusion) should be constant, giving 
as result of data fitting an n equal (or close) to 1 (zero-order transport kinetic, non-
Fickian diffusion). If n is lower than 1 (n<1), this indicates a reduced concentration 
gradient over time (first-order/pseudo first-order kinetic, Fig. 1). In the last scenario 
possible, the gradient of concentration ((c0d-ca)/x) is increasing over time, producing a 
positive deviation from linearity of mass transport profiles. This anomalous behaviour 
(associated to n>1) is generally called “super case” (Costa and Sousa Lobo, 2001, 




Under these premises, in this work, caffeine and hydrocortisone (hydrophilic and a 
lipophilic drug, respectively) were the chosen drugs to be formulated into large 
unilamellar vesicle (LUV) dispersions of controlled size and tonicity. Drug transport 
studies were performed employing two different types of barriers; one with a low 
retention (regenerated cellulose) and another with a high retention (Permeapad® (Di 
Cagno et al., 2015)). Moreover, LUV compositions were altered by the addition of 
different amount of cholesterol (from 0 up to 25% w/w) to increase liposomal barrier 
rigidity. To evaluate the influence of osmotic stress on drug release kinetics from 
liposomes, liposomal dispersions were exposed to environment of different ionic 
strengths. The obtained experimental data were analysed by the means of linear and 
non-linear (Korsmeyer-Peppas) regression models. The results obtained from this 
study might provide a new insight into the drug release mechanism from liposomes, 
and might be relevant for the development of liposomal drug formulations intended 
for nose-to-brain drug delivery. 
 
2. Materials and methods 
2.1 Materials 
Caffeine, hydrocortisone, disodium hydrogen phosphate dihydrate (Na2HPO4·2H2O), 
sodium chloride (NaCl), sodium hydroxide (NaOH), sodium dihydrogen phosphate 
monohydrate (NaH2PO4·H2O), chloroform and methanol were purchased from 
Sigma-Aldrich Chemie GmbH (Steinheim, Germany). Lipoid S100 (SPC, soy-
phosphatidylcholine >94%) was kindly provided from Lipoid GmbH (Ludwigshafen, 
Germany) and Permeapad® barriers from InnoME GmbH (Espelkamp, Germany). 
 
2.2 Preparation of phosphate buffered saline (PBS) 
PBS of pH 7.4 and 65 mOsm/kg (namely PBS65) was prepared according to Wu et 
al. (2017). The measured osmolality (Semi-Micro Osmometer Model 4602, Knauer, 
Berlin, Germany) and pH (SensIONTM+PH31 pH meter, Hach, Barcelona, Spain) of 
the different PBS used in this study are represented in Table 1. To create isotonic 
PBS (namely PBSiso that exhibited same tonicity as the LUVs, approx. 
400 mOsm/kg), 0.05 g of NaCl was dissolved in1 L of PBS65. For the preparation of 
hypertonic PBS (PBShyper), 0.10 g of NaCl was dissolved into 1 L of PBS65 (tonicity 




200 g/L) were added to PBS65 in order to adjust its tonicity to PBShypo’s tonicity 
(approx. 100 mOsm/kg). 
 
2.3 Preparation of LUVs 
LUV dispersions were prepared following a method previously described (Wu et al., 
2017). In the case of cholesterol-LUVs (11 and 25% w/w), solutions of 
SPC/cholesterol (ratio of 9:1 w/w or 4:1 w/w) in chloroform were used as organic 
phase. LUV formulations containing caffeine were prepared by dissolving the drug in 
the PBS65 (2 mM), whereas in the case of hydrocortisone, the drug was dissolved in 
the organic phase together with lipids. 
 
2.4 Size, zeta potential and entrapment efficiency characterization 
LUV dispersions were diluted with PBS65 (same buffer used to prepare the LUVs) 
1:100 (v/v) and filtered through polyether sulfone membranes (0.2 µm pore size, 
VWR International, Radnor, USA) prior to size measurement. For the determination 
of the electrokinetic potential (ZP) on liposomes surface, LUV dispersions were 
diluted 1:20 (v/v) with freshly filtrated deionized water (0.2 µm pore size filter) and 
analysis conducted at room temperature (23-25°C) using the DTS1070 cell (Malvern, 
Worcestershire, UK). The liposomal size and ZP were measured using a Zetasizer 
Nano Zen 2600 (25°C, Malvern, Worcestershire, UK) as previously described (Wu et 
al., 2019). To determine the entrapment efficiency (EE), drug-loaded LUVs were 
separated from the unentrapped drug by ultracentrifugation (200 000 g, 10°C, 
30 min, Beckman model L8-70M with SW 60 Ti rotor, Beckman Instruments, 
California, USA) (Wu et al., 2019). The drug concentrations in both LUVs and 
supernatant (representing unentrapped drug concentration) were quantified 
spectroscopically (Spectra Max 190 Microplate, Spectrophotometer Molecular 
devices, Sunnyvale, USA) using wavelengths at 273 and 247 nm for caffeine and 
hydrocortisone, respectively. Two samples for each batch of formulations were 
measured minimum three times. Experiments were repeated in minimum duplicates 
(n≥2). 
 
2.5 In vitro diffusion study 
The in vitro diffusion studies of caffeine and hydrocortisone were performed 




PermeGear diffusion cells and systems, Hellertown, USA) following a previously 
described method (Wu et al., 2019). The acceptor compartment was filled with 5 mL 
PBS following Table 1. Regenerated cellulose (Visking dialysis tubing MWCO 12–
14 kDa, Medicell Membranes Ltd., London, UK), or alternatively, Permeapad® 
(InnoME GmbH, Espelkamp, Germany) was used as diffusion barrier and 
experiments were conducted at 35°C (Julabo 200F heating circulator, Julabo Inc., 
Allentown, USA). At time zero (start of the experiment), 0.3 mL of PBS (same 
composition as acceptor buffer) was topped with 0.5 mL of LUV dispersion (2 mM 
total drug concentration) in the donor compartment. As reference experiments, drug 
solution (caffeine, 2 mM) or suspension (hydrocortisone, 1 mM, thermodynamic 
solubility) in PBS65 were also analysed. Aliquots of 0.5 mL were withdrawn from the 
acceptor compartment and replaced with equal volumes of the respective PBS (with 
same tonicity) every 30 min over a period of 4 hours. 
 
2.6 Data analysis 
2.6.1 Resistance to drug transport determination (R) 
The resistance to drug transport through liposomal bilayer (RL,) was calculated 
according to Wu et al. (2019). In brief, the initial part of diffusional curves (up to 
2.5 hours) was used to calculate the drug flux (j) through the diffusion barrier, which 
was supposed to be constant during the experiment since the sink conditions were 
kept. The apparent permeability (P) was determined by normalizing the flux over the 
total initial concentration (cd) (see Eq.(3): 





The resistance to drug transport through liposomal bilayer (RL) (i.e. the reciprocal 
function of permeability through the liposomal bilayer, 1/PL) was calculated from the 
total resistance to drug transport (RT, measured in the liposomal dispersion 
experiments) and from the resistance to drug transport through the barrier (RB, 
measured in drug solution experiments) by Eq.(4): 
𝑅 = 𝑅 − 𝑅   (4) 
 




Drug transport constants (K) and transport exponents (n) of the different liposomal 
formulations were determined by fitting of the in vitro diffusion data to the Korsmeyer-
Peppas equation (see Eq.(1)) using the add-in DDSolver program (China 
Pharmaceutical University, Nanjing, China). Microsoft Office Excel (Microsoft 
Corporation, Redmond, USA) was used as built-in module of the DDSolver. The K 
and n were determined in the range of Mt/M∞ 0-60% (Costa and Sousa Lobo, 2001). 
 
2.7 Stability study 
LUVs containing 0, 11 and 25% w/w cholesterol were prepared for both model drugs 
(caffeine and hydrocortisone) in duplicates (n=2) as described in section 2.3. Each 
batch was divided into two aliquots and stored in the fridge (at 6°C) and at room 
temperature (at 22°C) away from light sources for 65 days in clear polypropylene 
tubes (VWR® High-Performance centrifuge tubes, VWR International, Radnor, USA). 
Samples were periodically withdrawn (72 hours, 14, 35 and 65 days after 
preparation) and analysed. The stability of liposomal dispersions was evaluated in 
terms of tonicity, vesicle size distribution, ZP and EE (analysis performed as 
described in section 2.2 and 2.4). Each sample was measured minimum four times. 
 
2.8 Statistical data evaluation 
Student’s t-test was used to determine the significance of difference between means 
of different data sets. Differences were considered significant for p≤0.050. 
 
3. Results 
3.1 Liposome characterization 
The general characteristics of liposomes used in the in vitro study are presented in 
Table 1 and 2. The LUV dispersions exhibited total initial tonicity of around 
400 mOsm/kg (Table 1). The mean sizes of liposomes were between 236 and 
374 nm (Table 2). Incorporation of cholesterol into the LUVs increased the mean 
sizes and polydispersity for caffeine-LUVs (p≤0.010 and 0.001, respectively), and 
similarly for hydrocortisone-LUVs with 25% w/w cholesterol (PI, p=0.000). All LUVs 
exhibited almost neutral surface charges. The EE was approximately 11% for 
caffeine-LUVs and considerably higher for hydrocortisone-LUVs (51-68%). The EE 
decreased significantly with increased amount of incorporated cholesterol especially 





3.2 In vitro diffusion study  
3.2.1 Drug diffusion studies 
In Fig. 2, the diffusion profiles of caffeine and hydrocortisone in aqueous solution as 
well as in liposomal dispersions (0% w/w cholesterol) are reported for both 
regenerated cellulose and Permeapad® barriers. As it can be seen, the drug diffusion 
profiles through the different barriers varied accordingly to the drug used; the 
formulation (aqueous solution or liposomal dispersion) and the barrier (regenerated 
cellulose or Permeapad®). Specifically, the amount of diffused drug was significantly 
higher for caffeine than for hydrocortisone for both barriers. For both drugs, the total 
amount of diffused drug after 2.5 hours was significantly higher (p<0.000) from 
solution in comparison to LUV dispersion when regenerated cellulose was employed 
as the barrier (Fig. 2a, 49±1 vs 35±2% for caffeine and 40±3 vs 16±3% for 
hydrocortisone, respectively). Similarly, the total amount of accumulated 
hydrocortisone in the acceptor medium was significantly higher for drug solutions in 
comparison to the liposomal formulations (cumulative diffused after 2.5 hours, 9±2 vs 
6%, p=0.004) when Permeapad® was employed as barrier (Fig. 2b right). 
Interestingly, when Permeapad® was employed (Fig. 2b, lower-left), the amount of 
caffeine accumulated in the acceptor medium from solution and liposomal dispersion 
was the same. 
 
3.2.2 RL under the influence of changed external environments 
In Fig. 3, the resistances to drug transport through liposomal bilayer (RL) are reported 
for all the formulations prepared, for both drugs (caffeine in Fig. 3a and 
hydrocortisone in Fig. 3b, respectively) and two different types of barriers 
(regenerated cellulose and Permeapad®). From these data, it appeared that the ionic 
strength of external environment had a remarkable impact on RL. Specifically, RL was 
lowest when caffeine-LUVs were exposed to hypotonic environments, medium in 
isotonic and significantly higher level for hypertonic environment (Fig. 3a). For 
hydrocortisone-LUVs (Fig. 3b), the RL values were considerably higher in comparison 
to the caffeine-LUVs in all circumstances. Similarly to caffeine-LUVs, the RL was 
found to be lower for hypotonic/isotonic environment and significantly (p<0.050) 
higher in hypertonic environment. The incorporation of cholesterol into the liposomal 




caffeine, a trend indicating reduction of RL with growing concentration of cholesterol 
was observed (white bars). The employment of a biomimetic barrier such as 
Permeapad® (grey bars) resulted in a slight reduction in RL absolute values for 
caffeine in comparison to regenerated cellulose even though the trend at different 
external environmental tonicity was respected. The same was observed for 
hydrocortisone, but in this case, a significant reduction of RL was observed with 
increasing concentration of cholesterol (Fig. 3a-b). 
 
3.2.3 Non-linear data fitting using Korsmeyer-Peppas model 
The in vitro diffusion data obtained in this study were fitted according to the 
Korsmeyer-Peppas equation, Eq.(1). For all data sets, the correlation coefficient (R2) 
was rather high (min. 0.96 up to 1.00, data are shown in supplementary material, 
Fig.A.1-2) indicating a good correlation within experimental data and Eq.(1). From the 
data fitting, the transport constants (K, Fig. 4) and transport exponents (n, Fig. 5) 
were determined. The K values were much higher for caffeine (ranged between 8 
and 25, Fig. 4a) in comparison to hydrocortisone (from 1 to 8, Fig- 4b). It is worth 
mentioning that K values were significantly different for regenerated cellulose (white 
bars) and Permeapad® (grey bars) and these differences were higher for 
hydrocortisone than for caffeine. 
As already observed for RL, a clear correlation between K and environmental ionic 
strength was found. Specifically, the higher ionic strength in the external 
environment, the lower were the K value (Fig. 4, 0% w/w cholesterol). This 
phenomenon was more evident when using regenerated cellulose (white bars) as a 
barrier rather than Permeapad® (grey bars). In fact, no significant difference was 
determined in K values between the hypotonic and isotonic environments employing 
Permeapad® as barrier for both drugs. Interestingly, the experiments carried out on 
the regenerated cellulose barrier maintained a similar trend for caffeine-LUVs, even 
though increasing amounts of cholesterol were incorporated into LUV’s lipid bilayer 
(Fig. 4a, 0-25% w/w cholesterol). Differently, hydrocortisone seemed to somehow be 
less affected to the environmental ionic strength by the presence of cholesterol in the 
liposome’s membrane (Fig. 4b, 0-25% w/w cholesterol). 
The n values determined for caffeine-LUVs using regenerated cellulose as barrier at 
all tonicity conditions (Fig. 5a, white bars) ranged between 0.74-0.92. The n in 




comparison to both isotonic and hypertonic values (Fig. 5a). For the caffeine-LUV 
experiments carried out with biomimetic Permeapad® barrier (Fig. 5a, grey bars), n 
values were closer to 1, ranging between 0.83-0.97. For hydrocortisone-LUVs 
(Fig. 5b), n values were generally higher than caffeine-LUVs and in case of 
Permeapad®, they were even superior than 1. Moreover, an increasing trend in n 
values with increased cholesterol amount was detected employing regenerated 
cellulose. This trend was not evident for Permeapad® where the highest n values 
were detected at 11% w/w cholesterol. 
 
3.3 Liposomal stability 
The stability data obtained for the different liposomal dispersions stored at two 
different temperatures (6°C and 22°C) are reported in Table 3. As it can be seen, the 
tonicity of all the LUV dispersions were relatively stable over the 65 days period. The 
mean sizes and PI of caffeine-LUVs were relatively stable when stored up to 65 days 
at 6°C. The caffeine-LUVs formulations stored at room temperature (22°C) exhibited 
significant shifts in size distribution to smaller sizes (p≤0.016) and narrower PI 
(p≤0.031) after approx. 14 days for the formulations with 0 and 11% w/w cholesterol. 
For the hydrocortisone-LUVs, the mean sizes and PI varied quite remarkably at both 
storage temperatures. 
All LUV dispersions exhibited rather neutral zeta potentials right after formation, but 
became significantly more negative (p<0.05) after storage. For the caffeine-LUVs, the 
increase in ZP was more significant for the samples stored at 22°C, especially for the 
LUVs with no cholesterol (change up to 40 mV). For the hydrocortisone-LUVs, the 
samples stored in the fridge (6°C) exhibited significant variation in ZP as well as 
those stored at room temperature (p≤0.050). However, in this case, the ZP changes 
were rather small in magnitude (maximum variation of 5 mV). 
The EE of caffeine-LUVs with various amount of cholesterol incorporated in the 
phospholipid bilayer (0, 11 and 25% w/w) showed a mean EE of 13% and maximum 
variation of 6% during a period of 65 days of storage at 6°C. Surprisingly, when the 
same formulations were stored at 22°C, increase of EE up to 40, 30 and 19% could 
be found for caffeine-LUVs with 0, 11 and 25% w/w cholesterol, respectively. Those 
results indicated that the liposomal integrity probably changed during storage and for 
these reasons, as an additive information, pictures of all the different LUV dispersions 




differences in the sample appearance (see supplementary material, Fig.B.1). As it 
can be seen, the visual perception of caffeine-LUVs dispersions with 0% w/w 
cholesterol stored at 22°C had a more transparent/opaque colour than those stored 
at 6°C with a more white colour (Fig.B.1a, upper-right compared to upper-left). On 
the contrary, the hydrocortisone-LUVs (0-25% w/w cholesterol) showed more stable 
EE with a maximum variation of 4% (Table 3). These results emphasize the 
relevance of investigating LUV dispersion’s stability as changes in size, surface 




4.1 Liposome characterization 
LUV dispersions used in this work were prepared aiming to be suited for nasal 
delivery. For optimal transport through the nasal epithelium, the vesicles should 
exhibit a size of 10-400 nm, neutral ZP and toncity around 300 mOsm (Bourganis et 
al., 2018, Homer et al., 2000, Illum, 2007, Ohwaki et al., 1987). LUVs’ tonicity, sizes, 
PI, ZP and EE were found to be in the same order of magnitude as those employed 
in previous studies (Wu et al., 2019). 
As expected, the incorporation of the neutrally charged cholesterol into the lipid 
bilayer (consisting of neutrally charged SPC) did not induce any significant change in 
the surface charge of the liposomes. 
In comparison to hydrocortisone-LUVs, the sizes and PI of caffeine-LUVs, were more 
affected by the cholesterol incorporation in the phospholipid bilayer, which might be 
related to the drugs localization inside the LUVs (Briuglia et al., 2015, Leite et al., 
2018). 
The incorporation of cholesterol into liposomal membranes significantly affected the 
EE of hydrocortisone, whereas the caffeine-LUVs were not affected. This might be 
explained by the different affinity of drugs for the liposomal bilayer (Di Cagno and 
Stein, 2019) and cholesterol’s affinity for the lipid bilayer. In fact, the negative effect 
of cholesterol on EE for lipophilic compounds is well-documented (Ali et al., 2010, 
Mohammed et al., 2004). From the obtained results, it was evident that cholesterol 
prevented, to a certain degree, hydrocortisone embedding into the liposomal bilayers 





4.2 In vitro diffusion study 
The current methods used to determine the release from liposomes are the filtration, 
ultracentrifugation, solid phase extraction and dialysis-based methods. The filtration 
and ultracentrifugation are two methods that with the help of mechanical forces 
separate the nanocarriers from the released drug. However, these methods are not 
suitable for easily deformable nanocarriers such as liposomes, as the separation 
procedure might disrupt the nanocarrier leading to overrated release (Solomon et al., 
2017). For this reason, solid phase extraction is considered to be a more gentle 
method, and has been successfully applied to separate free drug from liposomes (Xie 
et al., 2018). However, some of the limitations with this method are that it is not suitable 
for all types of release medium, and is dependent on the medium composition (i.e. bile 
salts, ions, proteins), therefore the efficiency of separation can be influenced 
(Nothnagel and Wacker, 2018). Probably that is why the dialysis-based methods are 
more favoured, and in this study, we used the classical Franz diffusion cell set up to 
monitor the release from liposomes because of its convenience, cost-effectiveness and 
simplicity. 
 
4.2.1 Drug diffusion from drug solution and drug-loaded LUVs 
The dialysis-based method used in this study allowed us to quantify the amount of 
drug that diffused through a diffusion barrier. However, this method does not 
measure the direct release from the liposomal carrier. For correct interpretation, it 
has been proposed to use reference experiment of free drug solution (Wacker, 2017). 
For this reason, we have presented here the drug diffusion profiles from solution and 
LUVs through two different diffusion barriers. 
The regenerated cellulose barrier is highly permeable to small and neutrally charged 
molecules and the drug diffusion rate through the barrier is highly controlled by the 
drug concentration gradient between the both sides of the barrier (Bartels et al., 
2005, Benavente, 1984, Nothnagel and Wacker, 2018). On the other hand, the 
biomimetic Permeapad® barrier consists of a lipid layer in between two support 
sheets (Di Cagno and Bauer-Brandl, 2014). In contact with aqueous solution, the lipid 
layer is assumed to create tightly packed vesicles mimicking the structure of 
biological membranes (Di Cagno et al., 2015). In other words, the Permeapad® 
barrier represents a biomimetic barrier capable of discriminating drug permeability 




distribution coefficient at neutral pH (LogD7.4) plays a key role in the net drug mass 
transport through the barrier (Brandl et al., 2007, Nothnagel and Wacker, 2018). 
As represented in Fig. 2, the total amount of diffused drug from caffeine formulations 
was much lower (37-57% according to the formulation tested) when studied with 
Permeapad® in comparison to regenerated cellulose barriers (Fig. 2a-b). On the other 
hand, for hydrocortisone formulations, a reduction of 63-78% could be observed. As 
expected, hydrocortisone was more retained by Permeapad® in comparison to 
caffeine, due to its higher lipophilicity (logD7.4 of 1.6 for hydrocortisone in comparison 
to 0.0 for caffeine) (Zhu et al., 2002). 
As reported in previous studies (Di Cagno et al., 2015, Fadda et al., 1998, Wu et al., 
2017, Wu et al., 2019), the drug diffusion rate was lower for liposomal dispersions in 
comparison to drug solutions when analysed on regenerated cellulose barrier 
(Fig. 2). Surprisingly, this difference was not evident when Permeapad® was 
employed. This interesting finding indicates that, when biomimetic barrier was 
employed, the differences in drug transport properties within different formulations 
were reduced if not annulled. This can be by reason of the biomimetic barrier is the 
limiting step of the permeation in this case, reducing the impact of the formulation on 
the total drug transport kinetic. However, for hydrocortisone, a small difference 
between diffusion from drug solution or liposomal formulation was detectable, 
indicating that this phenomena is highly drug dependent. 
To evaluate better the liposomal bilayer’s contribution to changed drug diffusion 
profiles across the different barriers, we decided to report the RL as shown in the next 
sections. We also incorporated various amount of cholesterol into the liposomal 
bilayer (0-25% w/w) to study the relationship between liposomal rigidity and drug 
release. Moreover, we exposed the LUVs to different environmental tonicity to see if 
this could affect the drug release. 
 
4.2.2 Influence of cholesterol on RL 
Liposomes containing hydrophilic molecules might experience leakage due to 
cholesterol induced lipid bilayer reconstruction (Briuglia et al., 2015, Schullery, 1977). 
The effect cholesterol has on the SPC liposomes and the release properties from 
them can be translated from the calculated RL values. The decreasing RL values 
indicated that more drug was diffusing out of the nanocarrier. In agreement with the 




hydrocortisone-LUVs (Fig. 3b) when the amount of incorporated cholesterol 
increased from 0 to 25% w/w. 
On the other hand, it has also been argued that liposomes containing cholesterol 
should exhibit higher liposomal bilayer rigidity and the resistance to drug transport 
(RL) should increase as compared to liposomes made of plain SPC (Leite et al., 
2018, Milon et al., 1986). Surprisingly, the findings from this study seem to deviate 
from the reported literature. This fact can be explained by the variations of 
unentrapped drug concentration in the different formulations. As shown in Table 2, 
the hydrocortisone entrapment was strongly affected by the presence of cholesterol, 
whereas this was not found for the caffeine-LUVs. Specifically, only minimal changes 
in the unentrapped drug concentration for caffeine-LUVs with various amount of 
cholesterol could be measured (ranged between 1758 to 1773 µM), whereas 
hydrocortisone-LUVs showed unentrapped drug concentrations of 798, 838 and 
992 µM for 0, 11 and 25% w/w cholesterol, respectively. The higher the unentrapped 
drug concentration, the higher the concentration gradient (Eq. 2) and therefore the 
flux through the membrane. It should be underlined that these data are in agreement 
with previous reports of supersaturation induced by liposomal formulations (Di Cagno 
and Luppi 2013).  
 
4.2.3 Influence of ionic strength on RL 
Early works have shown that large unilamellar vesicles are susceptible to osmotic 
stress induced vesicle size changes (Mui et al., 1993, Sun et al., 1986). Liposomes 
have the tendency to swell when exposed to hypotonic environments. As a result of 
the swelling, the liposomal membrane becomes thinner and this can contribute to 
increased release from liposomes (i.e. reduced RL) (Ahumada et al., 2015, 
Alam shibly et al., 2016, Polozov et al., 2001). On the contrary, when liposomes are 
exposed to hypertonic environments, liposomes shrink and the liposomal membrane 
might become less permeable to drug permeation (i.e. higher RL) (Ahumada et al., 
2015, Fujiwara and Yanagisawa, 2014, Ohno et al., 2009). Our results were in 
agreement with the literature (Ahumada et al., 2015, Alam shibly et al., 2016, 
Fujiwara and Yanagisawa, 2014, Ohno et al., 2009, Polozov et al., 2001). For almost 
all caffeine-LUV formulations, the RL was significantly lower in hypotonic environment 
and highest for the hypertonic environment (Fig. 3a). Similar trend was also observed 




As it can be seen in Fig. 3a, the RL values were negative for the caffeine-LUVs when 
experiments were conducted using Permeapad® barriers. This result indicate that, in 
some cases, linear regression applied for data treatment and RL calculation, even 
though feasible, might lead to incomplete- or miss-interpretation of the data. This 
might be due to the experimental set up conditions where the drug release is highly 
influenced by the equilibrium across the diffusion barrier.  
One upcoming apparatus for drug release study from liposomes is the flow-through 
USP 4 (Tang et al., 2019, Yuan et al., 2017). This apparatus provides continuous 
flow of the release medium into a cell containing the drug formulation. The release 
medium with instant released drug is then pumped through a separation device (e.g. 
dialysis-based device) to remove liposomal drug, and the collected sample can be 
measured in situ at predetermined time points. The advantages with this method 
include its continuous renewal of the release medium, and the easily varied medium 
composition according to the solubility of the drug. Moreover, the apparatus can 
easily adjust variables such as temperature, flow rate, and detection wavelength. 
Sample measurements can be automatic, and relatively little manual work is 
required. However, due to the fact that relatively few companies develop the flow-
through cells, and the complexity of the apparatus, this method is still not mainstream 
(Solomon et al., 2017). 
The main purpose of this study was not to improve the experimental set up 
conditions, but to better interpret the obtained diffusion data collected from available 
equipment in our laboratory. It has to be mentioned that even though the flow-
through USP 4 drug release assay might be a superior method, and has shown some 
promising results for studying release from liposomes (Tang et al., 2019, Yuan et al., 
2017), this method is still limited by the barrier properties that separates the 
liposomal drug from released drug. Therefore, more processing of the diffusion data 
is still required for correct interpretation of the release mechanism from liposomes 
(Jain and Jain, 2016, Solomon et al., 2017, Wacker, 2017). 
Two of the most common mathematical methods used to study non-linear diffusion 
profiles are the Higuchi and Korsmeyer-Peppas model. In this study, we investigated 
the diffusion data employing the Korsmeyer-Peppas model. 
 




Since the aim of this study was to investigate the contributing alterations in liposomal 
bilayer properties relevant for drug release, the Korsmeyer-Peppas model was 
chosen due to its ability to provide the descriptive information on both release kinetics 
and mechanism of drug release. It should be underlined that the data we have been 
fitting to the model refer to the diffusion through low retention/high retention barriers, 
however, the data also reflect (as described in Fig. 1) the release kinetics from the 
nanocarriers. 
The parameter K indicated the constant drug transport that can be seen intuitively as 
directly proportional to the drug release kinetics from LUVs. In fact, higher K indicated 
faster drug release. On a contrary, lower value of K indicated a low transport kinetic 
and therefore poor drug release from nanocarriers. Interestingly, caffeine-LUVs 
generally expressed higher K values in comparison to hydrocortisone-LUVs (Fig. 4a 
and 4b). This was expected, since caffeine is known for its high permeability through 
phospholipid barriers (Di Cagno et al., 2015, Flaten et al., 2006). It should be 
underlined that K and RL were in rather good agreement; the higher the RL, the lower 
value of K, and vice versa. As seen before for RL, K also seemed to be highly 
influenced by changes in the ionic strengths of external environments. Specifically, 
the higher the increase in the external ionic strength (consequently shrinkage of 
liposomes) the K became lower, indicating a clear reduction of drug release from 
liposomes.  
The K changed more drastically in response to the environment when the 
regenerated cellulose barriers were employed in comparison to the Permeapad® 
barriers. This implies that, when biomimetic barriers were employed (i.e. higher 
retention barrier), the drug formulation plays a minor role in the net final drug 
transported through the barrier. This was also an interesting finding, highlighting the 
fact that dialysis barriers were extremely efficient to measure formulation kinetics but 
not necessarily predictive for in vitro-in vivo correlations. 
The advantage with the non-linear fitting approach was that a larger part of the 
experimental data was efficiently fitted (Mt/M∞ up to 60%) and seemed to better 
represent the drug diffusion kinetics from liposomes. Moreover, using this data 
treatment approach, there was no need to measure reference sample (i.e. drug 
solution). The application of Korsmeyer-Peppas model resulted in the time-efficient 




Under the influence of osmotic stress, the drug release kinetics of both caffeine 
(Fig. 4a) and hydrocortisone (Fig. 4b) from liposomes exhibited less variations in K 
when cholesterol was incorporated in the bilayers (0 vs 25% w/w). The more stable K 
values in different environmental ionic strengths indicated that the liposomal 
sensitivity to osmotic influences decreased. Possible explanation could be that 
cholesterol embedment into the liposomal bilayer decreases its flexibility (Leite et al., 
2018). 
The advantage with the Korsmeyer-Peppas model was the mechanistic 
considerations this model permitted, describing the drug release mechanism from 
liposomes by providing the transport exponent, n. In order to have a Fickian diffusion 
process, when no boundaries are present, n should be equal to 0.5, whereas values 
of n between 0.5 and 1 indicates non-Fickian diffusion and are indications of 
boundary region affecting the passive drug diffusion (Costa and Sousa Lobo, 2001). 
For the regenerated cellulose experiments (Fig. 5), n values for caffeine were always 
lower than 1. The lowest value of n measured for the diffusion of caffeine was in 
hypotonic environment (0.75-0.78) when the lipid bilayers should be the most 
stretched and therefore with the lowest resistance (Fig. 3) (Ahumada et al., 2015, 
Alam shibly et al., 2016, Polozov et al., 2001). Interestingly, when liposomes were 
exposed to isotonic and hypertonic environments, the n value increased remarkably 
(between 0.83 and 0.92). This variation in n indicated that the diffusion of caffeine 
was moving even further from a Fickian behaviour. This can be very well explained 
by the increasing resistance of caffeine transport through liposomal bilayers induced 
by vesicles’ shrinkage (Ahumada et al., 2015, Fujiwara and Yanagisawa, 2014, Ohno 
et al., 2009). Considering the experiments with regenerated cellulose barrier, in the 
case of hydrocortisone, n values were higher than for caffeine ranging between 0.86 
and 0.98. This finding suggests that hydrocortisone was from the start diffusing in a 
more controlled manner from the liposomal bilayer. The release profile of 
hydrocortisone seemed to be less affected by the changes in ionic strengths of 
liposomal surrounding environment (as observed in previous studies (Wu et al., 2017, 
Wu et al., 2019)). 
For the Permeapad® experiments, the n were found relatively more stable and were 
less affected by changes in the external environment of LUVs. As mentioned 
previously, it was plausible that the higher retention of Permeapad® in comparison to 





4.3 Formulation stability 
All LUV formulations prepared in this study retained a stable tonicity upon storage at 
both 6 and 22°C (Table 3). Stable tonicity is an important parameter considering the 
overall stability of liposomal suspensions (Grit and Crommelin, 1993). 
The more stable LUV dispersions in terms of size, PI and EE were the ones stored at 
6 rather than at 22°C, as expected. Moreover, low temperatures (4-6°C) are the 
recommendable storage conditions for liposomes (Grit and Crommelin, 1993). 
Instability of LUV dispersions in terms of drug loading can be described as the 
leakage of originally-associated liposomal content during storage. As expected, the 
hydrocortisone-LUVs exhibited stable EE up to 65 days at both 6 and 22°C 
independently of the amount of incorporated cholesterol. Surprisingly, the EE of 
caffeine-LUVs stored at 22°C seemed to increase over time. Similar increase in drug 
loading upon storage has been reported for other small hydrophilic compound such 
as rivastigmine (MW of 250 g/mole (Pubchem, 2019c)). Caffeine has MW of 
194 g/mole (Pubchem, 2019a). In the study carried out by Arumugam et al., an 
increase in EE of rivastigmine in liposomes was measured after 3 months of storage 
in comparison to freshly prepared drug-loaded liposomes (Arumugam et al., 2008). 
This might be an indication that the liposomal bilayer structure is permitting drug to 
pass through the liposomal membrane considering that we did not remove the 
unentrapped drug from the formulation. Analysing the samples visually, the caffeine-
LUV dispersions without cholesterol had a more transparent/opaque colour in 
comparison to the formulations with cholesterol (11-25% w/w). The increase in the 
EE for those formulations were probably due to drug migration to equilibrium in the 
samples as if the liposomal bilayers were no longer present. However, it could be 
observed that the changes in caffeine entrapment were not evident when cholesterol 
was in the lipid bilayer; it is well known that cholesterol stabilizes phospholipid 
bilayers (Briuglia et al., 2015, Grit and Crommelin, 1993). 
Taking into account all the variables measured, LUVs with 11% w/w cholesterol 
seemed to be the most stable formulation and exhibited suitable storage profiles in 
terms of size distribution, ZP and EE for the development of drug-loaded LUVs 
intended for nose-to-brain targeted drug delivery. 
We are currently testing several drugs with different lipophilicity as well as charge to 






Drug release from LUVs was significantly affected by the ionic strengths of the external 
environment confirmed by both linear (zero order) and non-linear (Korsmeyer-Peppas) 
regression models. Korsmeyer-Peppas model was proven to be suitable to analyse all 
drug transport data obtained in this study, providing important information on the 
release mechanism from the carrier in addition to being time efficient (less controls 
needed) unlike the zero order approximation. The drug release from LUVs could be 
tailored by the incorporation of cholesterol, and LUVs with 11% w/w cholesterol 
seemed to be the optimal liposomal composition in terms of stability and 
responsiveness to osmotic stress. In spite of the fact that regenerated cellulose is 
considered to be a standard, simpler and cheaper barrier used for the transport study, 
the Permeapad® appeared a more reliable when it comes to in vitro-in vivo correlation 
due to closer similarities to biological membranes. The results obtained in this work 
are rather relevant as the data can be utilized for the development of liposomal 
formulations intended for nose-to-brain targeted drug delivery. 
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Fig. 1: Schematic representation of the in vitro diffusion study using the dynamic 
dialysis method. The amount of drug accumulated in the acceptor compartment is 
directly influenced by the drug release rate from liposome (KI) and the drug transport 
rate through a diffusion barrier (K). The mechanism of drug release from liposomes 
can be defined by the transport exponent (n), obtained from the order of the fitted curve 
according to the Korsmeyer-Peppas equation. 
 
Fig. 2: In vitro diffusion study of caffeine (○) and hydrocortisone (∆) from solutions 
(filled symbols) and LUV dispersions (0% w/w cholesterol, empty symbols) through 
regenerated cellulose (a) or, alternatively, Permeapad® (b) as barriers in isotonic 
conditions. Results represent the mean ± standard deviation (n=3, *p≤0.050, 
**p≤0.010, ***p≤0.001). 
 
Fig. 3: Resistance to drug transport through liposomal bilayers (RL) containing various 
amount of cholesterol (0, 11 and 25% w/w) for caffeine (a) or hydrocortisone (b). 
Diffusion experiments were carried out employing regenerated cellulose (white bars) 
or, alternatively, Permeapad® (grey bars) barriers and exposing the LUV dispersions 
to isotonic, hypotonic and hypertonic environments (tonicity difference of 0 and ±300 
mOsm/kg within inner core of liposomes and external environment), respectively. 
Results represent the mean ± standard deviation (n=3, *p≤0.050, **p≤0.010, 
***p≤0.001). 
 
Fig. 4: Transport constant (K) obtained from non-linear data fitting of diffusion 
experimental data for caffeine- (a) or hydrocortisone- (b) LUV dispersions with various 
amount of cholesterol incorporated in the phospholipid bilayer (0, 11 and 25% w/w). 
Diffusion experiments were carried out employing regenerated cellulose (white bars) 
or alternatively, Permeapad® (grey bars) as barriers. LUV formulations were exposed 
to isotonic, hypotonic, and hypertonic environments (tonicity difference between inner 




Results represent the mean ± standard deviation (n=3, *p≤0.050, **p≤0.010, 
***p≤0.001). 
 
Fig. 5: Transport exponent (n) obtained from non-linear data fitting of diffusion 
experimental results for caffeine-(a) or hydrocortisone- (b) LUV dispersions with 
various amount of cholesterol incorporated in the phospholipid bilayer (0, 11 and 
25% w/w). Diffusion experiments were carried out employing regenerated cellulose 
(white bars) or, alternatively, Permeapad® (grey bars) as barriers. LUV formulations 
were exposed to isotonic, hypotonic, and hypertonic environments (tonicity difference 
between inner core and external environment of liposomes of 0 and ±300 mOsm/kg), 
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Fig.A.1: Fitting of caffeine diffusion experimental results to the Korsmeyer-Peppas 
model. Diffusion experiments were carried out employing regenerated cellulose (a) or 
alternatively, Permeapad® (b) as the barriers. The drugs were formulated in LUV 
dispersions with various amount of cholesterol incorporated in the phospholipid 
bilayers (0, 11 and 25% w/w) and the LUV dispersions were exposed to isotonic, 
hypotonic and hypertonic environments (tonicity difference of 0 and ±300 mOsm/kg 
within inner core of liposomes and external environment). Results represent the mean 
± standard deviation of three parallel experiments (n=3, *p≤0.050, **p≤0.010, 
***p≤0.001). 
 
Fig.A.2: Fitting of hydrocortisone diffusion experiment results to the Korsmeyer-
Peppas model. Diffusion experiments were carried out employing regenerated 
cellulose (a) or alternatively, Permeapad® (b) as barriers. The drugs were formulated 
in LUV dispersions with various amount of cholesterol incorporated in the phospholipid 
bilayers (0, 11 and 25% w/w) and the LUV dispersions were exposed to isotonic, 
hypotonic and hypertonic environments (tonicity difference of 0 and ±300 mOsm/kg 
within inner core of liposomes and external environment). Results represent the mean 
± standard deviation of three parallel experiments (n=3, *p≤0.050, **p≤0.010, 
***p≤0.001). 
 
Fig.B.1: Photographs of LUV-dispersions with caffeine (a) or hydrocortisone (b) and 
various amount of cholesterol incorporated in the phospholipid bilayers (0, 11 and 25% 
w/w) after 65 days storage at 6 and 22°C. Each tube present one replicate out of total 







Table 1: Experimentally determined osmolality and pH for all LUV dispersions and 

















0 420 ± 11 
PBShypo 119 ± 10 7.5 ± 0.1 
PBSiso 418 ± 10 7.3 ± 0.0 
PBShyper 718 ± 12 7.2 ± 0.0 
11 392 ± 12 
PBShypo 95 ± 16 7.6 ± 0.0 
PBSiso 386 ± 5 7.3 ± 0.0 
PBShyper 693 ± 23 7.2 ± 0.0 
25 388 ± 4 
PBShypo 88 ± 8 7.5 ± 0.0 
PBSiso 393 ± 4 7.3 ± 0.0 
PBShyper 692 ± 8 7.2 ± 0.0 
Hydrocortisone 
0a 383 ± 5 
PBShypo 83 ± 5 7.6 ± 0.0 
PBSiso 384 ± 5 7.3 ± 0.0 
PBShyper 683 ± 5 7.2 ± 0.0 
11 405 ± 5 
PBShypo 105 ± 5 7.6 ± 0.0 
PBSiso 405 ± 5 7.3 ± 0.0 
PBShyper 705 ± 5 7.2 ± 0.0 
25 383 ± 19 
PBShypo 86 ± 16 7.6 ± 0.0 
PBSiso 385 ± 16 7.3 ± 0.0 
PBShyper 687 ± 15 7.2 ± 0.0 
an=3  
 
Table 2: Measured size (average diameter), polydispersity index (PI), ζ-potential (ZP) 
and entrapment efficiency (EE) for LUV dispersions used in the in vitro release study. 
Results represent mean ± standard deviation (n=2). 
LUVs 
Cholesterol 










0 236 ± 36 0.25 ± 0.02 -3.7 ± 1.0 12 ± 1 
11 289 ± 55* 
0.34 ± 
0.04* 






-3.5 ± 1.1 10 ± 1*** 
Hydrocortisone 
0a 246 ± 30 0.25 ± 0.01 -3.5 ± 1.0 68 ± 5 
11 248 ± 38 0.24 ± 0.02 -4.1 ± 1.1 60 ± 3*** 
25 261 ± 47 
0.35 ± 
0.03*** 
-5.2 ± 1.1 51 ± 3*** 









Table 3: Liposomes characteristics under storage at 6 and 22°C over a period of 65 days. Changes were monitored by measuring 
the tonicity of the LUV dispersions (osmolality), liposomal size (average diameter), polydispersity index (PI), ζ-potential (ZP), and 
entrapment efficiency (EE). Results represent mean ± standard deviation (n=2). 









































13 ± 1 
 
- - - - - 
14 
 





14 ± 0 
 







15 ± 1* 
35 
 





15 ± 0* 
 







31 ± 6** 
65 
 





13 ± 2 
 

















9 ± 1 
 
- - - - - 
14 
 





13 ± 1*** 
















16 ± 3*** 
 
















16 ± 4*** 


















10 ± 1 
 
- - - - - 
14 
 





11 ± 1 
















11 ± 1 

















13 ± 1* 





















74 ± 1 
 
- - - - - 
14 
 







71 ± 1** 








69 ± 2** 
35 
 







70 ± 1** 
 







70 ± 2** 
65 
 







78 ± 1** 

















64 ± 2 
 
- - - - - 
14 
 





61 ± 1* 








63 ± 1 
35 
 







63 ± 1 








65 ± 1 
65 
 







65 ± 2 

















55 ± 2 
 
- - - - - 
14 
 







53 ± 0 
 







54 ± 1 
35 
 














58 ± 2 
65 
 





53 ± 0 
 







54 ± 1 
*p≤0.050, **p≤0.010, ***p≤0.001 when compared to the control (measurement on day 3). 








Fig. 1: Schematic representation of the in vitro diffusion study using the dynamic 
dialysis method. The amount of drug accumulated in the acceptor compartment is 
directly influenced by the drug release rate from liposome (KI) and the drug transport 
rate through a diffusion barrier (K). The mechanism of drug release from liposomes 
can be defined by the transport exponent (n), obtained from the order of the fitted curve 





Fig. 2: In vitro diffusion study of caffeine (○) and hydrocortisone (∆) from solutions 
(filled symbols) and LUV dispersions (0% w/w cholesterol, empty symbols) through 
regenerated cellulose (a) or, alternatively, Permeapad® (b) as barriers in isotonic 





Fig. 3: Resistance to drug transport through liposomal bilayers (RL) containing various 
amount of cholesterol (0, 11 and 25% w/w) for caffeine (a) or hydrocortisone (b). 
Diffusion experiments were carried out employing regenerated cellulose (white bars) 
or, alternatively, Permeapad® (grey bars) barriers and exposing the LUV dispersions 
to isotonic, hypotonic and hypertonic environments (tonicity difference of 0 and ±300 
mOsm/kg within inner core of liposomes and external environment), respectively. 






Fig. 4: Transport constant (K) obtained from non-linear data fitting of diffusion 
experimental data for caffeine- (a) or hydrocortisone- (b) LUV dispersions with various 
amount of cholesterol incorporated in the phospholipid bilayer (0, 11 and 25% w/w). 
Diffusion experiments were carried out employing regenerated cellulose (white bars) 
or alternatively, Permeapad® (grey bars) as barriers. LUV formulations were exposed 
to isotonic, hypotonic, and hypertonic environments (tonicity difference between inner 
core and external environment of liposomes of 0 and ±300 mOsm/kg), respectively. 







Fig. 5: Transport exponent (n) obtained from non-linear data fitting of diffusion 
experimental results for caffeine-(a) or hydrocortisone- (b) LUV dispersions with 
various amount of cholesterol incorporated in the phospholipid bilayer (0, 11 and 
25% w/w). Diffusion experiments were carried out employing regenerated cellulose 
(white bars) or, alternatively, Permeapad® (grey bars) as barriers. LUV formulations 
were exposed to isotonic, hypotonic, and hypertonic environments (tonicity difference 
between inner core and external environment of liposomes of 0 and ±300 mOsm/kg), 
respectively. Results represent the mean ± standard deviation (n=3, *p≤0.050, 
**p≤0.010, ***p≤0.001). 
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